Product Images Gabapentin

This is a description of potential symptoms related to a health condition. The symptoms mentioned include: lack of coordination, viral infection, difficulty with speaking, tremor, swelling (usually of legs and feet), feeling tired, fever, feeling drowsy, nausea and vomiting, jerky movements, difficulty with coordination, double vision, and unusual eye movement. These symptoms may indicate a neurological or viral illness and should be evaluated by a healthcare professional.*

Gabapentin Dosage Based on Renal Function This table provides dosing guidelines for gabapentin based on renal function. The total daily dose is divided based on the patient's creatinine clearance, which is a measure of kidney function. The table includes different dosage regimens for different ranges of creatinine clearance. The dosages are given in milligrams per day and are divided into three categories: TID (three times a day), BID (two times a day), and QD (single daily dose). For patients with a creatinine clearance greater than or equal to 60 mL/min, the total daily dose ranges from 900 to 3600 mg, with specific dosages for each regimen. For patients with a creatinine clearance ranging from greater than 30 to 59 mL/min, the total daily dose ranges from 400 to 1400 mg, also with specific dosages for each regimen. For patients with a creatinine clearance ranging from greater than 15 to 29 mL/min, the total daily dose ranges from 200 to 700 mg, again with specific dosages for each regimen. For patients with a creatinine clearance of 15 mL/min or lower, the daily dose should be reduced in proportion to the creatinine clearance. Exact dosages are not provided in the text. The table also includes a post-hemodialysis supplemental dose for patients undergoing hemodialysis, with specific dosages indicated based on creatinine clearance. These doses range from 1250 to 3500 mg. The abbreviations TID, BID, and QD are defined in the text as three times a day, two times a day, and single daily dose, respectively. Note: The output contains some errors and inconsistencies.*

This text provides information about controlled PHN (postherpetic neuralgia) studies using Gabapentin. It includes the duration of the studies, dosages of Gabapentin administered, and the number of patients receiving Gabapentin and placebo. Study 1 lasted for 8 weeks, with a target dose of 3600 mg/day, and had 113 patients receiving Gabapentin and 116 receiving placebo. Study 2 lasted for 7 weeks, with target doses of 1800 and 2400 mg/day (given in 3 divided doses), and had 223 patients receiving Gabapentin and 111 receiving placebo. The total number of patients included in these studies was 336 for Gabapentin and 221 for placebo.*

This text appears to be a mathematical formula for calculating something related to age, weight, and serum creatinine levels. However, without further context or information, it is difficult to determine the exact purpose or meaning of the formula.*

Not available.*